Lyon et Gentilly, France, 10 February 2026, 6.00 pm CET – THX Pharma (Theranexus), a biopharmaceutical company specializing in the treatment of rare neurological diseases, and Biocodex, an independent international pharmaceutical group, announce the execution of a strategic licensing agreement to advance the development of two drug candidates in three rare diseases with high unmet medical needs: Batten disease with Batten-1, and Gaucher disease and Niemann-Pick disease type C with TX01.
View the Full Press Release